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Abstract 
Excessive amount of reactive oxygen species (ROS) in the body are implicated with many 
pathological disorders. The increase in ROS production can be triggered by exposure to ionizing 
radiation (e.g. X-rays & gamma-rays) and excessive exposure to ultraviolet radiation (e.g. UV-B). 
In this study, nitroxide radical-containing redox nanoparticles (RNPN) with an effective ROS 
scavenging activity was developed. Moreover, its therapeutic efficacy against ionizing radiation 
(X-rays) and excessive exposure to UV-B were evaluated in vivo. 
The damaging and lethal effects of ionizing radiation can be reduced and prevented with 
the use of radiation protective agents otherwise known as radioprotectors. Radioprotectors are 
compounds that are administered before exposure to ionizing radiation to reduce its damaging 
effects, including radiation-induced lethality [1-2]. A potent radioprotector can be used in many 
applications: clinical radiotherapy, space travel, radiation site clean-up, radiological terrorisms 
and military attacks, nuclear accidents and day-to-day protection of radiation workers [3]. The use 
of radioprotectors is particularly important for the protection of normal cells in radiotherapy. 
Radiotherapy remains an important tool in modern cancer management, nearly half of all newly 
diagnosed cancer patients receive radiotherapy at some point in the course of their disease [4]. 
However, like any cancer treatment and procedures, radiotherapy has been associated with various 
side effects. The early and late side effects of radiation limit the clinical dose and might affect the 
long-term health quality of the patients. With an increasing number of cancer patients, preventing 
or reducing its side effects becomes a priority [5-6].  At present, there are only two radiation 
protective compounds (amifostine and palifermin) that have been approved by the US FDA (Food 
and Drug Administration) for use in radiation therapy [7]. Amifostine is a cytoprotective agent 
used in chemotherapy and radiotherapy [8]. The later drug, palifermin, gained US FDA approval 
in 2004 as a recombinant protein which has the ability to decrease the incidence and duration of 
severe oral mucositis in patients of chemotherapy and radiotherapy [9]. However, the use of these 
compounds has been limited due to some serious adverse effects [8]. These lead to the evaluation 
of several compounds (e.g. phytochemicals) for possible use in radiation protection [10-14]. But 
most of these compounds have not successfully reached approval for clinical use due to issues 
regarding its stability/instability, rapid excretion, toxicity [15], and low therapeutic potential. 
Therefore, there is a need to develop new agents with high-stability, long retention time, and high 
therapeutic effects. This study aims to develop a nanomedicine against the damaging and lethal 
effects of ionizing radiation and against the UV-B-induced skin inflammatory disorders in vivo. 
The specific objectives of this study includes the following: 
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1. Design, synthesis, and preparation of nitroxide radical-containing redox nanoparticles 
(RNPN); 
2. Determine its blood circulation and biodistribution profile; 
3. Evaluate its protective effects against whole-body ionizing radiation (X-rays); and 
4. Evaluate its ability to attenuate UV-B radiation-induced skin inflammatory disorders. 
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